RLM.L Regulatory News (RLM)

Director Dealing

12 August 2014 - PuriCore plc (LSE: PURI) (the "Company"), a global company focused on safe and effective protection against the spread of infectious pathogens, today announces a director dealing, in accordance with the Disclosure and Transparency Rules. On 11 August 2014, the following Director notified the Company that he had purchased ordinary shares of 10p each in the share capital of the Company ("Shares"), as set out below.

Enquiries:

About PuriCore

PuriCore plc (LSE: PURI) is a global company focused on safe and effective protection against the spread of infectious pathogens without causing harm to human or animal health or to the environment. PuriCore's antimicrobial technology and complementary products are used in a well-established core business and emerging sectors of two broad markets: Food & Agriculture and Health Sciences. In the Food & Agriculture market, PuriCore's portfolio is used by thousands of US supermarket retailers, including three of the top-five, to provide savings in labour costs and improvements in inventory loss and to address cross contamination of pathogens on fresh produce and floral products. In the Health Sciences market, PuriCore's breakthrough wound care technology is used to treat chronic and acute wounds including diabetic ulcers and burns in humans, for atopic dermatitis as private-labelled dermatologic treatments for humans, and to manage wounds in all species of companion and farm animals in the animal health segment. PuriCore is headquartered in Malvern, Pennsylvania. To receive additional information on PuriCore, visit www.puricore.com.